MSFT 429.615 -0.3167% AAPL 240.32 0.3047% NVDA 139.4 0.5554% GOOGL 171.825 0.1953% GOOG 173.39 0.237% AMZN 211.2705 0.266% META 594.855 0.3416% AVGO 167.49 0.5886% TSLA 354.0867 -0.841% TSM 195.79 0.715% LLY 809.885 1.2609% V 313.24 -1.0769% JPM 247.365 0.4528% UNH 606.6797 -0.3024% NVO 110.44 1.6288% WMT 92.555 -0.0918% LVMUY 127.67 0.1333% XOM 117.962 0.095% LVMHF 640.0 -0.039% MA 528.05 -0.6229%
Last update at 2024-12-03T14:53:00Z
Here's Why Cardinal Health (CAH) is a Strong Value Stock
Thu 17 Oct 24, 01:40 PMHere's Why Cardinal Health (CAH) is a Strong Momentum Stock
Wed 16 Oct 24, 01:50 PMCardinal Health (CAH) Stock Dips While Market Gains: Key Facts
Mon 14 Oct 24, 10:15 PMAre Investors Undervaluing Cardinal Health (CAH) Right Now?
Fri 11 Oct 24, 01:40 PMIs Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year?
Fri 11 Oct 24, 01:40 PMQ3 2024 T2 Biosystems Inc Earnings Call
Fri 11 Oct 24, 11:19 AMCAH Stock May Gain Following the Distribution Deal With T2 Biosystems
Wed 09 Oct 24, 04:26 PMCardinal Health (CAH) Stock Moves -0.2%: What You Should Know
Mon 07 Oct 24, 10:15 PMCardinal Health (CAH) Stock Moves -0.17%: What You Should Know
Tue 01 Oct 24, 10:15 PM| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | 638.00M | -769.00000M | 323.00M | -3772.00000M | 1751.00M |
| Minority interest | -1.00000M | 1.00M | 3.00M | 3.00M | 2.00M |
| Net income | 261.00M | -932.00000M | 611.00M | -3693.00000M | 1363.00M |
| Selling general administrative | 4834.00M | 4557.00M | 4533.00M | 4572.00M | 4480.00M |
| Selling and marketing expenses | 4834.00M | 4557.00M | 4533.00M | - | - |
| Gross profit | 6889.00M | 6545.00M | 6778.00M | 6868.00M | 6834.00M |
| Reconciled depreciation | 692.00M | 692.00M | 783.00M | 913.00M | 1000.00M |
| Ebit | 1774.00M | 1648.00M | 1841.00M | 1773.00M | 2060.00M |
| Ebitda | 2466.00M | 2340.00M | 2624.00M | 2686.00M | 2718.00M |
| Depreciation and amortization | 692.00M | 692.00M | 783.00M | 913.00M | 658.00M |
| Non operating income net other | 4.00M | -24.00000M | 31.00M | -15.00000M | -15.00000M |
| Operating income | 727.00M | 1648.00M | 1841.00M | 1773.00M | 2060.00M |
| Other operating expenses | 203242.00M | 179700.00M | 160673.00M | 151150.00M | 143801.00M |
| Interest expense | 93.00M | 149.00M | 180.00M | 238.00M | 294.00M |
| Tax provision | 376.00M | 163.00M | -289.00000M | -79.00000M | 386.00M |
| Interest income | 93.00M | 147.00M | 182.00M | 341.00M | 307.00M |
| Net interest income | -93.00000M | -149.00000M | -180.00000M | -238.00000M | -294.00000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | 1043.00M | 2260.00M | 1322.00M | 5870.00M | -327.00000M |
| Other items | - | - | - | - | - |
| Income tax expense | 376.00M | 163.00M | -289.00000M | -79.00000M | 386.00M |
| Total revenue | 205012.00M | 181364.00M | 162467.00M | 152922.00M | 145534.00M |
| Total operating expenses | 5119.00M | 4881.00M | 4984.00M | 5096.00M | 5101.00M |
| Cost of revenue | 198123.00M | 174819.00M | 155689.00M | 146054.00M | 138700.00M |
| Total other income expense net | -1039.00000M | -2417.00000M | -1518.00000M | -5545.00000M | -309.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 262.00M | -932.00000M | 612.00M | -3693.00000M | 2137.00M |
| Net income applicable to common shares | 261.00M | -933.00000M | 611.00M | -3696.00000M | 1363.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total assets | 43417.00M | 43878.00M | 44453.00M | 40766.00M | 40963.00M |
| Intangible assets | 1472.00M | 1774.00M | 2105.00M | 2918.00M | 3430.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 2362.00M | 2021.00M | 3944.00M | 1707.00M | 1946.00M |
| Total liab | 46268.00M | 44584.00M | 42659.00M | 38974.00M | 34633.00M |
| Total stockholder equity | -2851.00000M | -706.00000M | 1794.00M | 1792.00M | 6330.00M |
| Deferred long term liab | 8653.00M | 9299.00M | 9670.00M | 8594.00M | 2945.00M |
| Other current liab | 42.00M | 2842.00M | 96.00M | 2231.00M | 2122.00M |
| Common stock | 2747.00M | 2813.00M | 2806.00M | 2789.00M | 2763.00M |
| Capital stock | 2747.00M | 2813.00M | 2806.00M | 2789.00M | 2763.00M |
| Retained earnings | -534.00000M | -280.00000M | 1205.00M | 1170.00M | 5434.00M |
| Other liab | 8278.00M | 9299.00M | 9670.00M | 8237.00M | 2939.00M |
| Good will | 4609.00M | 5855.00M | 7989.00M | 8357.00M | 8378.00M |
| Other assets | 606.00M | 953.00M | 951.00M | 732.00M | 1006.00M |
| Cash | 4043.00M | 4717.00M | 3407.00M | 2771.00M | 2531.00M |
| Cash and equivalents | 4043.00M | 4717.00M | 3407.00M | 2771.00M | 2531.00M |
| Total current liabilities | 33706.00M | 30550.00M | 27624.00M | 23615.00M | 24109.00M |
| Current deferred revenue | 3059.00M | - | 2957.00M | - | - |
| Net debt | 658.00M | 598.00M | 2829.00M | 4004.00M | 5500.00M |
| Short term debt | 792.00M | 580.00M | 871.00M | 10.00M | 452.00M |
| Short long term debt | 792.00M | 580.00M | 871.00M | 10.00M | 452.00M |
| Short long term debt total | 4701.00M | 5315.00M | 6236.00M | 6775.00M | 8031.00M |
| Other stockholder equity | -4913.00000M | -3125.00000M | -2183.00000M | -2063.00000M | -1788.00000M |
| Property plant equipment | 2462.00M | 2361.00M | 2360.00M | 2792.00M | 2356.00M |
| Total current assets | 33833.00M | 32935.00M | 31048.00M | 25940.00M | 25747.00M |
| Long term investments | - | - | - | - | 46.00M |
| Net tangible assets | -8933.00000M | -8338.00000M | -8300.00000M | -9486.00000M | -5480.00000M |
| Short term investments | - | - | - | - | - |
| Net receivables | 11344.00M | 10561.00M | 9103.00M | 8264.00M | 8448.00M |
| Long term debt | 3909.00M | 4735.00M | 5365.00M | 6740.00M | 7579.00M |
| Inventory | 15940.00M | 15636.00M | 14594.00M | 13198.00M | 12822.00M |
| Accounts payable | 29813.00M | 27128.00M | 23700.00M | 21374.00M | 21535.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | 1.00M | 3.00M | 3.00M | 3.00M | 2.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -151.00000M | -114.00000M | -34.00000M | -104.00000M | -79.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 2747.00M | 2813.00M | 2806.00M | 2789.00M | 2763.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | -534.00000M | -280.00000M | 1205.00M | 1170.00M | 5434.00M |
| Treasury stock | -4914.00000M | -3128.00000M | -2186.00000M | -2066.00000M | -1790.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1041.00M | -8346.00000M | 951.00M | 1185.00M | 1052.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 9584.00M | 10943.00M | 13405.00M | 14826.00M | 15216.00M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | 3909.00M | 4735.00M | 5365.00M | 6765.00M | 7579.00M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -454.00000M | 22.00M | 25.00M | 866.00M | -15.00000M |
| Change to liabilities | 2718.00M | 3428.00M | 2325.00M | -162.00000M | 1864.00M |
| Total cashflows from investing activities | -454.00000M | 567.00M | -378.00000M | 493.00M | 338.00M |
| Net borrowings | -579.00000M | -885.00000M | -570.00000M | -1401.00000M | -1102.00000M |
| Total cash from financing activities | -3051.00000M | -2463.00000M | -1317.00000M | -2200.00000M | -2293.00000M |
| Change to operating activities | - | 293.00M | 452.00M | 6550.00M | 193.00M |
| Net income | 262.00M | -932.00000M | 612.00M | -3693.00000M | 1365.00M |
| Change in cash | -674.00000M | 1310.00M | 636.00M | 240.00M | 768.00M |
| Begin period cash flow | 4717.00M | 3407.00M | 2771.00M | 2531.00M | 1763.00M |
| End period cash flow | 4043.00M | 4717.00M | 3407.00M | 2771.00M | 2531.00M |
| Total cash from operating activities | 2839.00M | 3122.00M | 2429.00M | 1960.00M | 2722.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 692.00M | 692.00M | 783.00M | 913.00M | 1000.00M |
| Other cashflows from investing activities | 2.00M | 932.00M | 22.00M | 2.00M | 681.00M |
| Dividends paid | 525.00M | 559.00M | 573.00M | 569.00M | 577.00M |
| Change to inventory | -340.00000M | -1071.00000M | -1584.00000M | -409.00000M | -551.00000M |
| Change to account receivables | -947.00000M | -1526.00000M | -904.00000M | 82.00M | -751.00000M |
| Sale purchase of stock | -2000.00000M | -1000.00000M | -200.00000M | -350.00000M | -600.00000M |
| Other cashflows from financing activities | 53.00M | -19.00000M | 26.00M | 120.00M | -14.00000M |
| Change to netincome | 1421.00M | 2238.00M | 746.00M | -1321.00000M | -401.00000M |
| Capital expenditures | 481.00M | 387.00M | 400.00M | 375.00M | 328.00M |
| Change receivables | -947.00000M | -1526.00000M | -904.00000M | 82.00M | -751.00000M |
| Cash flows other operating | -967.00000M | 293.00M | 452.00M | 6550.00M | 196.00M |
| Exchange rate changes | - | - | 11.00M | -13.00000M | 1.00M |
| Cash and cash equivalents changes | -666.00000M | 1226.00M | 745.00M | 240.00M | 768.00M |
| Change in working capital | 464.00M | 1124.00M | 289.00M | 6061.00M | 755.00M |
| Stock based compensation | 96.00M | 81.00M | 89.00M | 90.00M | 82.00M |
| Other non cash items | 1356.00M | 2150.00M | 160.00M | -450.00000M | -397.00000M |
| Free cash flow | 2358.00M | 2735.00M | 2029.00M | 1585.00M | 2394.00M |
Sector: Healthcare Industry: Medical Distribution
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CAH Cardinal Health Inc |
-0.035 0.03% | 122.44 | 166.11 | 14.71 | 0.12 | 16.07 | 0.12 | 19.78 |
| MCK McKesson Corporation |
2.30 0.37% | 623.59 | 17.95 | 14.53 | 0.20 | 5.04 | 0.22 | 12.17 |
| COR Cencora Inc. |
0.45 0.18% | 250.32 | 23.39 | - | - | - | ||
| HSIC Henry Schein Inc |
-0.985 1.29% | 75.52 | 24.12 | 14.04 | 0.74 | 2.50 | 0.95 | 13.33 |
| SHPMF Shanghai Pharmaceuticals Holding Co. Ltd |
-0.0001 0.0079% | 1.27 | 7.71 | 5.45 | 0.03 | 0.57 | 0.03 | 0.88 |
Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
7000 Cardinal Place, Dublin, OH, United States, 43017
| Name | Title | Year Born |
|---|---|---|
| Mr. Jason M. Hollar | CEO & Director | 1973 |
| Ms. Jessica L. Mayer | Chief Legal & Compliance Officer | 1970 |
| Mr. Stephen M. Mason | Chief Exec. Officer of Medical Segment | 1972 |
| Ms. Patricia M. English | Sr. VP & Interim CFO | 1980 |
| Ms. Mary C. Scherer | Sr. VP & Chief Accounting Officer | NA |
| Ms. Michelle Greene | Exec. VP & Chief Information Officer and Global Bus. Services | NA |
| Mr. Kevin Moran | VP of Investor Relations | NA |
| Ms. Ola M. Snow | Chief HR Officer | 1968 |
| Mr. Craig Cowman | Exec. VP of Strategic Sourcing & Manufacturer Services | NA |
| Ms. Deborah L. Weitzman | Chief Exec. Officer of Pharmaceutical Distribution | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...